CytoMed Therapeutics Announces Collaboration with MD Anderson Cancer Center
CytoMed Therapeutics, a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel allogeneic cell-based immunotherapies for the treatment of human cancers, today announced it has entered into a research collaboration agreement with The University of Texas MD Anderson Cancer Center (“MD Anderson”) in Houston, Texas, to use gamma-delta T cells (gdTc) for the treatment of acute myeloid leukemia (AML) and breast cancer.
AML is the most common type of acute leukemia in adults and is likely to worsen quickly if untreated. However, there are not many treatment options available for AML. Similarly, the incidence rate of breast cancer globally is high, and patients may quickly run out of treatment options, especially if they suffer from triple-negative breast cancer. This collaboration aims to develop new treatment modalities for unmet needs of AML and breast cancer patients at an affordable cost.
The study will be led by Venkata Lokesh Battula, Ph.D., associate professor of Leukemia at MD Anderson. Under the terms of the two-year agreement, research teams will evaluate the application of allogeneic gdTc by CytoMed on various subtypes of AML and breast cancer in vitro and in vivo. The study is expected to use patient-derived AML cells and breast cancer cell lines for investigation. The results of the study are intended to be part of an Investigational New Drug Application with the U.S. Food and Drug Administration for the allogeneic use of gdTc for blood and solid cancers.
CytoMed received approval in January 2023 from Singapore’s Health Science Authority to conduct a first-in-human Phase I clinical trial for the use of its lead allogeneic chimeric antigen receptor T-cell (CAR-T) product candidate (CTM-N2D) against several blood and solid tumor cancers, including colorectal, lung, liver, ovarian, lymphoma and multiple myeloma [ANGELICA Trial, NCT05302037]. This is a single-site, open-label, dose-escalating trial at the National University, Hospital, Singapore, an established major public hospital.
“Interest in the potential of our allogeneic immunotherapy platform to provide additional treatment options has been strong,” said Dr. Tan Wee Kiat, Chief Operating Officer at CytoMed. “International collaborations, like the current collaboration with MD Anderson Cancer Center, are a key part of our strategy to maximize our impact.”
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more